Israeli startup AiVF, which uses AI to increase the predictability and success rates of IVF treatments, raised a $25M Series A led by Insight Partners
Context & Ripple Effects
AiVF's $25M Series A landed amid a run of Israeli AI startups converting research into commercial platforms — a month earlier, RGo Robotics emerged from stealth with a $20M Series A for perception tech, and Ibex Medical Analytics had already pushed AI diagnostics past $100M in total funding. Insight Partners leading the round put one of Israel's most active growth investors behind a clinical-application bet rather than infrastructure.
In hindsight, the round reads as an early marker of the fertility-automation wave: three years on, Conceivable Life Sciences raised $50M to automate embryologists' work, at-home diagnostics player Inito pulled in a $29M Series B, and reporting has documented robots and AI fertilizing embryos through IVF, with at least 20 babies born. AiVF's focus on predicting treatment success sits at the front end of that same pipeline.
First-order effects
- AiVF gets the capital to scale its IVF predictability platform across clinics, while Insight Partners secures an early position in clinical AI ahead of the sector's larger later rounds.
- IVF clinics using the platform gain data-backed odds on treatment outcomes, shifting embryo-selection and protocol decisions from clinician judgment alone toward model-assisted calls.
Second-order effects
- The round helped validate fertility AI as a fundable category, pulling follow-on capital into adjacent layers of the stack — Conceivable's larger embryology-automation raise and Inito's at-home diagnostics round both target steps of the same patient journey.
- Clinics face a build-vs-buy choice across prediction, embryology, and diagnostics vendors, pressuring incumbents to license or partner rather than develop these capabilities internally.
Third-order effects
- If the funding cadence holds, IVF moves from an artisanal, lab-dependent process toward standardized, software-scored pipelines — with regulators eventually forced to define oversight for algorithms that influence which embryos are transferred and which treatments proceed.
The trend: Venture capital is moving up the fertility stack from AI decision-support toward full automation of embryology, with each successive round funding a deeper step of the IVF process.